Novo shares jump 7% ahead of US prescription data for Wegovy pill

Core Viewpoint - Shares of Novo Nordisk increased by 7% on Friday, reaching their highest level since September, indicating strong market performance ahead of anticipated U.S. prescription data for the Wegovy pill [1] Company Summary - Novo Nordisk's stock performance places it among the top gainers in Europe, reflecting positive investor sentiment and market confidence in the company's products [1]